This week
setmelanotide's two-year data just landed at obesityweek — the obesity drug that isn't a glp-1
ObesityWeek 2026 is running this week in Washington, D.C. — the year's biggest obesity medicine gathering, with every major GLP-1 program in the spotlight. While most conference coverage this week has tracked retatrutide's pre-filing timeline and next-generation dual agonists, Rhythm Pharmaceuticals stepped up on November 16 with something the mainstream obesity conversation doesn't cover often enough: two-year outcomes from TRANSCEND, the Phase 3 trial of setmelanotide in acquired hypothalamic obesity. The numbers are worth pausing on. Patients treated continuously with setmelanotide for two years achieved a mean -18.8% BMI reduction. Patients who switched from placebo to setmelanotide after year one reached -16.5% by the two-year mark. Among adult participants specifically, the continuous-treatment figure was -21.2%. This is not an investigational drug awaiting an FDA decision. Setmelanotide — marketed as Imcivree — is already approved, with an expanded indication for acquired hypothalamic obesity cleared in March 2026. ObesityWeek is extending that story with durability data the original approval package hadn't reached yet. [Rhythm Pharmaceuticals released the ObesityWeek data on November 16](https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-presentation-new-data).
The molecule
setmelanotide activates the mc4 receptor — a hunger circuit with no glp-1 receptor in sight
Setmelanotide is a melanocortin-4 receptor agonist. That description puts it in entirely different pharmacological territory from semaglutide, tirzepatide, and every other GLP-1 or incretin-class drug currently dominating obesity coverage. The MC4 receptor sits in the hypothalamus as part of the leptin-melanocortin system — a brain-level circuit that governs appetite and energy balance. When this pathway functions normally, signals travel from leptin through POMC-producing neurons, through the MC4 receptor, and produce sustained appetite inhibition. In patients with genetic defects in POMC, LEPR, or PCSK1, or in Bardet-Biedl syndrome, or in patients whose hypothalamus was physically damaged by tumors, surgery, or radiation, that signal chain is disrupted. The hunger brake doesn't engage. Setmelanotide is designed to bypass the upstream defect and activate MC4R directly — targeted pharmacology for a specific identified biological failure, rather than a broad appetite-suppression effect built for general populations. The mechanism is as mechanistically precise as any approved peptide drug gets: broken pathway, specific receptor, clinical outcomes that follow. [PubMed's setmelanotide literature](https://pubmed.ncbi.nlm.nih.gov/?term=setmelanotide) documents both the mechanistic work and the full clinical program.
The public narrative
it gets filed under rare disease and left out of the conversation — the two-year data says something worth hearing
The standard obesity drug conversation in 2026 runs entirely through the GLP-1 lane: Ozempic, Zepbound, the pipeline behind them. Setmelanotide doesn't fit that frame, and coverage tends to reflect that. The drug is approved for specific genetic or acquired conditions — not for the broader obesity market GLP-1 drugs target — and the rare-disease label has functioned as a convenient reason to look past it. What that skipping misses: a drug producing -21.2% mean BMI reduction in adults, in a population with severe hyperphagia that doesn't respond to behavioral approaches, is achieving outcomes that compare favorably to some of the most-cited weight-loss numbers in the clinical literature. The comparison is imperfect — different populations, different mechanisms, different eligibility criteria — but the gap between setmelanotide's outcomes and the obesity conversation's framing of it as a footnote is worth noticing. ObesityWeek 2026 brings that tension into relief: a drug with two-year sustained outcome data presenting at the same conference where the next-generation GLP-1 pipeline is consuming all the coverage.
What the data says
transcend's two-year extension showed durability — the phase 3 that failed in 2026 tells the other half of the mc4 story
The TRANSCEND Phase 3 trial enrolled patients with acquired hypothalamic obesity — a condition caused by damage to hypothalamic tissue from craniopharyngiomas, pituitary tumors, radiation, or surgery that disrupts the brain's appetite regulation capacity. At the two-year ObesityWeek presentation, 81 of 125 patients who entered the long-term extension had completed analysis. Among those treated continuously, mean BMI dropped -18.8%. Among those who switched from placebo after year one, the reduction reached -16.5%. Adults tracked at -21.2% (continuous) and -21.0% (switched); pediatric patients showed BMI z-score changes of -1.71 and -1.49 respectively. Safety was consistent with prior trial experience; 52 of 125 participants had treatment-related side effects in year two, none classified as serious. [The March 2026 FDA approval of setmelanotide for acquired hypothalamic obesity was covered by AJMC](https://www.ajmc.com/view/fda-approves-setmelanotide-for-adult-and-pediatric-patients-with-acquired-hypothalamic-obesity) at the time, confirming the Phase 3 basis for the label. That positive story coexists with a harder data point: earlier in 2026, the EMANATE Phase 3 trial evaluated setmelanotide across four substudies in other rare genetic obesity conditions driven by MC4R pathway defects — and did not meet its primary endpoints in any of the four. [ClinicalTrials.gov's setmelanotide registry](https://clinicaltrials.gov/search?term=setmelanotide) documents the full trial footprint across all indications.
Approved — PeptideFactCheck stance
the approval is indication-specific and the two-year data extends it — the mc4r story has real limits and real receipts
Setmelanotide holds PeptideFactCheck's Approved evidence tier: regulatory certainty for labeled uses, not a blank check for every claim. In practice that means the TRANSCEND Phase 3, the March 2026 FDA label for acquired hypothalamic obesity, and the ObesityWeek two-year extension results form a coherent evidence package for a specific, well-defined patient population. The drug produces meaningful, durable BMI reduction in that population. That is what the data supports, and the tier is correct. What Approved does not do is extend the read beyond the labeled indication. The EMANATE failure earlier in 2026 is a real boundary — MC4R agonism doesn't work uniformly across every genetic subtype of melanocortin pathway disease, and the TRANSCEND success in acquired hypothalamic obesity should not be generalized into the substudies EMANATE tested. The obesity drug conversation's tendency to look past setmelanotide in favor of the GLP-1 pipeline is partly explainable: the GLP-1 market is bigger, the population eligible for setmelanotide is smaller, and acquired hypothalamic obesity doesn't have the cultural saturation of Ozempic. None of that changes what two years of TRANSCEND data look like for the patients who completed it. ObesityWeek gave setmelanotide a good week. The indication limits stayed exactly where they were. Source trail before certainty.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.